A New York hedge fund is proving to be an astute trader in NxStage Medical Inc., selling off more of its stake this week just ahead of a small slump in the company’s share price.
Caliper Life Sciences Inc. launched a new line of optical imaging reagents for its IVIS system.
The Hopkinton, Mass.-based lab equipment and services provider said its Rediject D-Luciferin Ultra reagent allows researchers to track injection quality because it comes with a pre-formulated tracking agent.
About 100,000 U.S. children are diagnosed with scoliosis, or abnormal lateral curvature of the spine, every year, according to a press release.
Axial’s ScoliScore AIS Prognostic is a saliva-based genetic test designed to predict the risk of progression of the condition in Caucasian children between 9 and 13 years old diagnosed with mild adolescent idiopathic scoliosis.
Pressure BioSciences Inc. débuted a pair of sample preparation kits for its pressure cycling device to extract proteins from worms.
The Easton, Mass.-based lab equipment maker said its ProteoSolve-CE NATIVE and ProteoSolve-CE STRINGENT kits allow researchers to extract proteins from the Caenorhabditis elegans nematode.
According to the data, overall heart function — as measured by the volume of blood pushed out of the heart and throughout the body with each heart beat — continued to rise after three years in patients treated with the Danvers, Mass.-based firm’s Impella 2.5 pump, compared with a similar assessment four months following the procedure.
A prominent Ohio cardiologist with ties to Massachusetts is joining the board of Endovalve, a New Jersey-based mitral valve repair firm, MedCity News reported.
Marc Gillinov, head of the Cleveland Clinic’s Center for Atrial Fibrillation and a co-founder of Wilmington, Mass.-based Viacor, was named to Endovalve’s scientific advisory board.
Analogic Corp. ended what officials called the company’s “most challenging year” in its more than 40-year history by swinging to a loss in the fourth quarter.
The Peabody medical imaging products maker reported a net loss of $285,000 for the three months ended July 31, compared to a $3.3 million profit for the same period last year.
It looks as though Boston Scientific Corp. might have left its heart (and some business) in San Francisco.
To say its been a rough week at the annual Transcatheter Cardiovascular Therapeutics meeting would be a grotesque understatement, as the Natick-based coronary stent colossus suffered a series of high-profile setbacks at the annual meeting of thousands of cardiologists from around the world.
Another study showing the ineffectiveness of rapid tests for Swine Flu has the Centers for Disease Control advising doctors and patients not to bother with the tests at all, the Reuters news service reported.
A study by researchers at Connecticut’s Greenwich Hospital and Greenwich Dept. of Health found that Thermo Fisher Scientific‘s Remel Xpect Flu A&B rapid test missed 53 percent of cases later confirmed by genetic tests.
Abele, a co-founder of medical device colossus Boston Scientific Corp., will join a board that already includes Ratan Tata, chairman of the Tata Group, one of the largest conglomerates in India; Alfred Ford, the current chairman of the Ford Motor Co. and grandson of Henry Ford; and former Ambassador John Palmer.